MPE Masterclass 2021
The MPE Masterclass 2021 was held virtually and included lectures on myeloma and AL amyloidosis diagnosis and treatment, discussions on access challenges across Europe, presentations on the impact of COVID-19 on the patient community, and workshops to support the capacity of patient organizations.
Watch below the recordings of the presentations given on the 2nd and 3rd July 2021.
MPE Masterclass 2021 | Welcome message
MPE Masterclass - A welcome message from Dr María Victoria Mateos
MPE Masterclass - A welcome message from Dr Mohamad Mohty
MPE Masterclass 2021 | The early detection and diagnosis of MGUS and SMM
MPE Masterclass 2021 | Immunotherapy in the treatment of myeloma and AL amyloidosis
Masterclass 2021 | COVID 19 and the effect on the treatment for myeloma and AL amyloidosis patients
MPE Masterclass 2021 | New developments and controversies in the myeloma treatment pathway
MPE Masterclass 2021 |Developments in AL amyloidosis diagnostic centres of expertise
MPE Masterclass 2021 | Palliative Care and quality of life
MPE Masterclass 2021 | MPE members response to and resiliency during COVID 19. Poland
MPE Masterclass 2021 | MPE members response to and resiliency during COVID 19. Israel
MPE Masterclass 2021 | Panel discussion on Minimal Residual Disease (MRD). Hans Scheurer
MPE Masterclass 2021 | Panel discussion on Minimal Residual Disease (MRD). Hans Jacobs
MPE Masterclass 2021 | Panel discussion on Minimal Residual Disease (MRD). Paula van Hennik
MPE Masterclass 2021 | Access to new treatments in CEE countries
MPE Masterclass 2021 | Myeloma related diseases
MPE Masterclass 2021 | Fundraising for patient groups and collaboration with industry
Annual Masterclass 2020
The MPE Annual General Meeting (AGM) 2020 was cancelled due to the COVID-19 outbreak. The educational programme planned to be held in the Annual Masterclass was replaced by the MPE Webinars series.
MPE AGM 2020 - Webinar on Myeloma and AL amyloidosis treatment updates
MPE AGM 2020 - Webinar on reimbursement and Health Technology Assessment (HTA) in Europe
MPE AGM2020 webinar series - Big data, the Harmony example
Watch the webinar on personalised medicines in myeloma and AL amyloidosis
Minimal Residual Disease (MRD) in myeloma and related diseases
Webinar on the impact of myeloma and AL amyloidosis in carers
Annual Masterclass 2019
MPE AGM 2019 outtakes
Myeloma Treatment Updates
Surrogate end-points in myeloma and AL amyloidosis
Measuring and utilising quality of life
AL Amyloidosis
The role of CAR-T
Annual Masterclass 2018
MPE Capacity Building Programme
Community Advisory Boards and case studies of MPE member groups
Rehabilitation, self-care and quality of life
Journey to a professional and empowered advocate
Clinical trials design and study endpoints
Myeloma related diseases
Drug access and affordability
Coping with a chronic disease
Update on diagnosis and treatment of AL amyloidosis
Annual Masterclass 2017
MPE dialogues - “Where are we now in myeloma and how does the future look like?”
Welcome, introductions and driving throught the conference
The European Atlas of Access to Myeloma Treatment
Update on current diagnosis and treatment of myeloma and related diseases
Clinical trials and drugs under development in myeloma and AL Amyloidosis
Treatment of myeloma in the light of access barriers
Patient advocate development strategies: how can an umbrella organisation help you
Annual Masterclass 2016
Treating myeloma. An update on the current myeloma treatment guidelines
Myeloma and Amyloidosis 101
What is multiple myeloma associated amyloidosis?
Advocacy session 1 – Patient involvement in clinical research
Welcome and introductions
The MPE Atlas: myeloma UK case study
Evidence based advocacy: implementing the MPE Atlas
Atlas Coaching Programme
Myeloma beyond C.R.A.B. An update on the current mueloma diagnosis guidelines